Pasithea Therapeutics Corp.
KTTAW
NASDAQ Capital Market0.01
USD
- -
- -
Pasithea Therapeutics Corp.
KTTAW
(NASDAQ Capital Market)
Recent
price
0.01
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Pasithea Therapeutics Corp. Pasithea Therapeutics Corp. (Nasdaq: KTTA; KTTAW) is a clinical-stage biotechnology company that discovers, researches, and develops innovative treatments for central nervous system (CNS) disorders, RASopathies, and cancers. The company focuses on its lead candidate PAS-004, a next-generation macrocyclic mitogen-activated protein kinase (MEK) inhibitor for neurofibromatosis type 1 (NF1)-associated plexiform neurofibromas, MAPK pathway-driven tumors including BRAFv600 and BRAF fusion tumors, and ETS2-driven diseases such as inflammatory bowel disease, primary sclerosing cholangitis, and ankylosing spondylitis; PAS-003, a development candidate for amyotrophic lateral sclerosis (ALS); and PAS-001, intended for schizophrenia. It operates primarily in the United States with global clinical trial sites across North America and Eastern Europe, targeting patients with unmet needs in neuropsychiatric, neurological, and oncological conditions. Pasithea Therapeutics Corp., founded in 2020 and headquartered at 1111 Lincoln Road, Suite 500, Miami Beach, Florida, leverages expertise in neuroscience, medicinal chemistry, and translational medicine to advance its pipeline through preclinical studies, Phase 1 trials, and decentralized clinical networks. Recent developments include the closing of a $5 million public offering in May 2025, generating additional proceeds from warrant exercises to fund research, clinical trials, and potential acquisitions or licensing related to CNS disorders and cancer treatments; the announcement on November 25, 2025, of a $1 million award from the ALS Association to study PAS-004's efficacy, safety, and tolerability in ALS; divestiture of dermatology assets in 2023 to streamline focus on CNS programs; and FDA clearance of its Investigational New Drug application for PAS-004 in 2022, followed by Phase 1 trial initiation.